Enovis Launches Next-Gen Laser Therapy System for Veterinary Market
Event summary
- Enovis Corporation launched CT-RevitL™, a next-generation veterinary laser therapy system, on July 13, 2026.
- The system is built on over 150 published studies on photobiomodulation (PBM) therapy.
- CT-RevitL features COMPASS technology for precise, calibrated dosing and reduced treatment variability.
- The launch aims to support practice growth by expanding treatment offerings and improving clinical outcomes.
The big picture
Enovis is capitalizing on the growing demand for drug-sparing alternatives in veterinary medicine. The launch of CT-RevitL positions the company as a leader in advanced laser therapy, aligning with broader industry trends toward non-invasive treatments and improved clinical outcomes. With over 15 years of experience in PBM laser therapy, Enovis aims to strengthen its market position through innovative technology and comprehensive clinical education.
What we're watching
- Market Adoption
- The pace at which veterinary practices adopt CT-RevitL will indicate its market penetration and competitive edge.
- Clinical Impact
- Whether the system's COMPASS technology can deliver consistent, measurable improvements in treatment outcomes.
- Revenue Growth
- How CT-RevitL contributes to Enovis' revenue growth through expanded treatment offerings and recurring demand for non-drug care.